Reported results
- As of September 30, 2026, cash and cash equivalents were $7.38 million, compared with $5.16 million at December 31, 2025.
- Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $5.09 million.
- Completed SYMON-II clinical study enrollment, exceeding the original target of 750 patients.
- Preliminary baseline analysis of 777 evaluable patients identified 140 deaths within 28 days, representing approximately 18% mortality.
Guidance
- Existing cash resources are estimated to support operations through the second quarter of 2027.
- Plans FDA 510(k) submission for Symphony IL-6 during the first half of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
